I own this one and am strictly a chart player, which is why I bought, but didn't Pfizer, or one of the other big pharmas, have a drug that failed in this arena (liver/kydney cancer) recently? Is that why the FDA told NEXM they could just pass by the second phase and go straight to the third, assuming they expand the parameters as per the suggestion? I know the NEXM drug was designated as having orphan status but maybe they will fast track it next. Given the pump runs on CYCC, GNVC, KERX and SNSS, ya gotta figure that a 50 cent dogshit stock like NEXM, what with the FDA suggestion to go to phase three, is a bit undervalued when compared to the aforementioned turds.
Weekly candlestick chart, along with the line chart, tells me she is going to the high 60s near term, but fundmentally, if they have a shot at doing something Pfizer failed at, I expect we will see it higher than 60-70 cents a share at some point in 2010. Likley we'll see speculation on the usual subjects of partnerships and buyouts blah blah blah. Place your bets.
News 
Market Data 
Discover 
